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coronary angiographic (QCA) analysis as ‘CAD’ (patients with ≥1 coronary stenosis
of ≥70% severity or ≥50% if left main stem) and ‘No CAD’ (Group 2).
Results: 54 patients (32.9%) had significant CAD prior to TAVI, with 10 (6.5%)
undergoing PCI prior to their procedure. The CAD group had more males (70.4% v
51.0%, p=0.02) and a greater proportion with previous PCI (27.8% v 11.5%, p=0.01).
[|#7#|][|#7#|]At a mean follow up of 337±275 days (mean±SD), the overall mortality
in the CAD group was higher (35.2% v 16.3%, p=0.007), as were 30-day (16.7% v
3.8%, p=0.005) and 12 month mortalities (31.5% v 14.4%, p=0.01). Kaplan Meier
analysis confirmed the increase in mortality with the presence of CAD (logrank=0.02).
The incidence of MACCE was not significantly different (35.2% v 23.1%, p=0.11).
[|#7#|][|#7#|]Amongst the 10 patients who underwent PCI in Group 1, 8 had single
vessel intervention and 2 had PCI to 2 vessels. Mortality in this sub-group was not
significantly different from the CAD patients who did not receive PCI (50% versus
31.8%, p=0.28).
Conclusion: The presence of significant CAD as defined by QCA analysis increased
overall, 30-day and 12 month mortality in patients after TAVI in our study. As yet, the
impact of PCI to significant CAD upon outcome after TAVI is not clear and will be
assessed in a prospective, randomised controlled trial.
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Background: The need for permanent pacemaker is a recognized complication of
Transcatheter aortic valve implantation (TAVI) with the CoreValve prosthesis. The
purpose of the present analysis was to evaluate the need of permanent pacemaker after
TAVI with the CoreValve prosthesis using the new Accutrak delivery system.
Methods: Between April 2008 and May 2011, a total of 195 consecutive patients with
symptomatic aortic valve stenosis underwent TAVI using the self expanding CoreValve
revalving prosthesis. In 124 patients the traditional delivery system (TS) and the
remaining were performed using the Accutrak delivery system.
Results: The mean age and logistic EuroSCORE was similar in both groups (TS vs.
Accutrak): 79.4 ± 6.7 vs. 78.3 ± 6.5 and 20.6 ± 13% vs. 18.6 ± 10%, respectively. The
procedural success rates were 97.5% for TS and 100% for Accutrak. There were no
significant differences in baseline ECG characteristics between patients who use the
traditional system compared with Accutrak: PR interval 153 ± 46 mm vs. 165 ± 30
mm, p = 0.127; LBBB 22 (20.2%) vs. 8 (12.7%), p = 0.213; RBBB 21 (19.3%) vs. 8
(12.7%) p = 0.268; anterior and posterior hemiblock, 28 (25.9%) vs. 12 (19.1%) p =
0.342. The depth of the prosthesis in the left ventricular outflow tract (LVOT) was
greater with TS compared with Accutrak (9.6 ± 3.2 mm vs. 6.4 ± 3 mm, p < 0.001),
and the need for permanent requirement pacemaker was higher with TS than Accutrak
(35.1% vs. 14.3%, p = 0.003).
Conclusion: The new Accutrak delivery System allows a better position of the
CoreValve prosthesis with less depth in the LVOT and this could be related to the lower
rate of permanent pacemaker
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Background: The safety and efficacy of a true percutaneous approach in transfemoral-
transcatheter aortic valve implantation (TAVI) have not been described in a large
prospective cohort. The purpose of this study was to evaluate the incidence of vascular
complications and the predictors of Prostar failure for this approach.
Methods: Among 337 patients included in our prospective TAVI database (October
2006 to April 2011), transfemoral-TAVI was performed in 208 patients. True
percutaneous approach was performed in 176 consecutive patients since March 2008.
Successful closure with Prostar was defined as adequate hemostasis without Prostar-
related vascular complications. We compared the clinical outcomes in our early and
late experience according to the VARC definitions. The first 88 cases defined the “early
experience group”.
Results: Patients were 83.0±7.2 years old and EuroSCORE 24.0±11.6%. The Edwards
valve was used in 136 cases (18-24Fr) and the CoreValve in 40 (18Fr). The sheath
outer diameter/minimal femoral diameter ratio (SFAR) was 0.96±0.14. Successful
closure was achieved in 91.2%, and was significantly increased (96.3% vs 86.8%,
p=0.045) in the late experience group. Cross-over to surgery was required in 2.2%.
Vascular complications occurred in 19.9%, and were significantly lower in the late
experience group (11.0% vs 26.5%, p=0.017). Major vascular complications (2.9% vs
14.0%, p=0.018) were decreased in the late experience group. Early experience
(HR:19.16, 95%CI:3.04-136.89, p<0.001), increased BMI (HR:1.34, 95%CI:1.04-1.72,
p=0.033) and SFAR (HR:98.07, 95%CI:1.12-8746.20, p=0.045) predicted Prostar
failure by multivariate analysis.
Conclusion: True percutaneous transfemoral-TAVI is feasible and associated with a
high rate of success and a low rate of complications after a learning phase. Other
predictors of failure are higher BMI and SFAR. Further application of this technique
provides less invasive approach to these high-risk patients.
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Background: Multiple medical reimbursement systems exist in Europe, which may
create unequal dissemination and coverage of innovative medical devices. Even in the
setting of regularly revised systems, uptake of new technology may be delayed leading
to unequal reimbursement.
Methods: This study analyzed the 2010 trends of transcatheter aortic valve
implantation (TAVI) rates in 14 countries (Medtronic CoreValve System and Edwards
Sapien). Implant data were gathered from BIBA Medical, a UK-based provider of
market analysis for the medical device industry. Demographic and economic data were
gathered from Eurostat, a statistical office of the European Union. Regression
techniques were used to explore the relationship between implant rate and a number
of key variables.
Results: In 2010, a total of 14,400 TAVI procedures were documented providing an
average country-based implant rate of 36.2 per million/Inhabitants. A seven-fold
difference in implantation rate existed between the highest and lowest implanting
countries (Germany, 77 per mil/inhab. vs. Norway 12 per mil/inhab.). Implant rates
were correlated with per-capita gross domestic product (GDP) (r2=0,015), health
expenditure (r2=0.15)and number of implanting centers in the country (r2=0.18). At
this time, only two European countries have a dedicated tariff for TAVI that is
applicable nationwide and covers both the device and the procedure (Germany €34,900,
France €28,477). Differences between country-specific tariffs depend on the method
of DRG calculation. In Austria, the TAVI tariff was made to equal that of surgical aortic
valve replacement. Countries such the UK and Italy have adopted case-by-case
funding. In countries such as Belgium and the Netherlands TAVI is funded by the
hospital-based budget.
Conclusion: Significant differences in TAVI rates exist among Europe; per-capita GDP,
health expenditure, implanting centers, and regional differences in reimbursement
policies may help explain these differences. These observations may help us to better
understand unequal patterns of dissemination and coverage of innovative medical
devices such as TAVI.
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Background: Transcatheter aortic valve implantation (TAVI) is a rapidly evolving
technique for high-risk patients with significant aortic stenosis. Suitable aortic annulus
sizes (AAS) for the 2 currently available devices range from 18-27 mm for the Edwards
SAPIEN Valve and 20-27 mm for the Medtronic CoreValve Prosthesis. Contrast-
enhanced multi-slice computed tomography (MSCT) has been established in recent
years for reproducible measurement of AAS. Aim of study was to obtain gender-related
values of AAS derived by MSCT in elderly, high-risk patients scheduled for TAVI and
to verify, if the currently available, CE marked TAVI devices are sufficient for the
treatment of the vast majority of this collective.
Methods: We retrospectively analyzed 1004 symptomatic patients (81.03+/-6.48 years,
range 48.51 to 98.53 years; 468 men (46.6%)) with severe AVS scheduled for TAVI
between 04/2005 and 10/2010. In all patients, a contrast-enhanced ECG-gated MSCT
(64-slice dual source CT scanner) was performed pre-interventionally as part of the
routine TAVI screening process. Measurement of AAS was performed by 3D-
multiplanar reconstruction. For the currently available TAVI devices, patients AAS
was classified in 3 subgroups: 1=AAS too small (< 18.0 mm); 2=AAS adequate (18.0
to 27.0 mm); 3=AAS oversized (> 27.0 mm).
Results: AAS in the overall population was 24.7+/-2.5 mm (mean+/-SD). AAS in men
was 26.1+/-2.3mm and in women 23.5+/-1.9mm. Comparing gender-related values
women showed a significantly smaller AAS (p=0.001). In 83.6% of patients, AAS was
within the required range (group 2). In 0.2% AAS was “too small” (group 1) whereas
in 16.2% of patients (group 3) AAS was “oversized” for the currently available devices.
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In summary, 16.4% of patients (group 1+3) were formally not treatable using TAVI.
Conclusion: The majority of patients with AVS scheduled for TAVI show suitable
AAS for current devices. Anyhow, a substantial number of patients are not eligible due
to oversized aortic annulus diameters. Consecutively, the development of larger
prostheses is crucial to embrace this not negligible minority of patients.
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Prognostic Impact of Permanent Pacemaker Implantation Among Patients
With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve
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Background: The occurrence of conduction abnormalities requiring the implantation
of a permanent pacemaker (PPM) in patients undergoing transcatheter aortic valve
implantation (TAVI) is not rare, with an incidence ranging between 5-30% in published
series. To investigate the impact of PPM on prognosis, we compared clinical outcomes
of patients with severe aortic valve stenosis undergoing TAVI in the following three
groups: (1) patients with PPM prior to TAVI, (2) patients with TAVI-related PPM and
(3) patients without PPM before and after TAVI.
Methods: A total of 351 consecutive patients (mean age 82.1±6.7 years, mean
logEuroscore 24.2±15.4%) with symptomatic aortic valve stenosis (mean gradient
44.6±16.3mmHg) undergoing TAVI with use of the 18F Medtronic CoreValve
prosthesis (n=293, 83.5%; transfemoral: 288, subclavian: 5) or the Edwards Sapien
prosthesis (n=58, 16.5%, transfemoral: 24, transapical: 34) were prospectively followed
in this two-center observational study. A total of 47 patients (13.4%) had a PPM prior
to TAVI (group 1), 98 patients (27.9%) received a PPM during the peri-procedural
period (group 2) and 206 patients required no PPM during follow-up (group 3). The
primary endpoint of the study was mortality at one year follow-up. Secondary
endpoints included in-hospital mortality as well as rates of stroke and myocardial
infarction in-hospital and at one year.
Results: Device success was 97.4% without differences between the three groups. In-
hospital and one-year follow-up was available in 100% of alive patients. Overall
in-hospital and one year mortality were 4.6% (16/351) and 22.8% (80/351),
respectively, without significant differences among the different study groups (see
table). Rates of in-hospital stroke, infarction and access site complication were 2.6%,
0.9%, 13.7%. Detailed clinical follow-up will be presented.
Conclusion: In this observational study, patients with severe aortic stenosis undergoing
TAVI had a similar survival independent of the need of PPM implantation, which
underlines the benign nature of this complication.
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Background: Periprocedural myocardial injury (PMI) is a common complication
during cardiac surgery and percutaneous coronary intervention and is an important
predictor for postprocedural cardiovascular morbidity and mortality. Very few data
have been reported about the occurrence of myocardial damage associated with
transcatheter aortic valve implantation (TAVI). Therefore, our purpose was to
investigate the incidence, the predictive factors and clinical consequences of PMI
during TAVI.
Methods: In a prospective observational single-centre study, we included 117 patients
(age 81±8 years, 46 male), who had undergone a TAVI with the Medtronic-CoreValve®
bioprosthesis. Serum CK-MB and cTnT levels were measured pre- and
postprocedurally. Periprocedural myocardial injury was defined as a postprocedural
increase of CK-MB and/or cTnT level above 5 times the upper reference limit, as
obtained from the Valve Academic Research Consortium.
Results: Following TAVI the incidence of PMI was 18%. Independent predictive
factors for PMI were procedural duration (minutes, OR: 1.04; 95%CI: 1.01-1.07),
preprocedural beta-blocker use (OR: 0.13; 95%CI: 0.03-0.51), peripheral arterial
disease (OR: 6.08; 95%CI: 1.47-25.13) and prosthesis depth (millimeters, OR: 1.28;
95%CI: 1.05-1.56). Mortality within 30 days following TAVI was 13%. Predictive
factors identified for 30-day mortality were PMI (OR: 10.89; 95%CI: 2.49-47.53),
preprocedural hospitalization (OR: 9.96; 95%CI: 2.32-42.66) and left ventricular mass
index (gr/m2, OR: 1.02; 95%CI: 1.00-1.03).
Conclusion: Following transcatheter aortic valve implantation, serum levels of both
CK-MB and cTnT increase, which reflects the occurrence of periprocedural myocardial
injury. A longer procedural duration, the absence of beta-blocker use, peripheral arterial
disease and a deeper prosthesis insertion are associated with PMI. Together with
preprocedural hospitalization and left ventricular mass, PMI
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Aortic valve calcium scoring (AVCS) is a predictor of significant paravalvular
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Background: Transapical aortic valve implantation (TA-AVI) has evolved as a routine
for selected high-risk patients. However, paravalvular leaks >1+ remain an unsolved
issue using current generation of transcatheter valve devices. The aim was to study the
impact of aortic valve calcification on paravalvular leaks and outcome using the
Edwards SAPIENTM prosthesis.
Methods: 120 consecutive patients (out of 307 TA-AVIs) with preoperative computed
tomography, age 82.6±6.2 years, 75.0% female, were included. Implanted prosthetic
valve sizes were 23 mm (n=31), and 26 mm (n=89), respectively. Mean logistic
EuroSCORE was 30.1±15.5 and mean STS-Score 12.8±7.9. ECG-gated cardiac CT
allowed to quantify the amount of calcification of aortic valve leaflets using a scoring
analogous to the Agatston calcium scoring of coronary arteries (AVCS). Paravalvular
leaks were assessed intraoperatively by echocardiography and angiography.
Results: All valves were implanted successfully. Mean AVCS in patients without
paravalvular leaks (n=66) was 2704±1510, with mild paravalvular leaks (n=31)
3804±2739 (p=0.05) and with moderate paravalvular leaks (n=4) 7387±1044
(p=0.002). There was a significant correlation between AVCS and paravalvular leaks
(r=0.334; p=0.001) indicating, of note, only a limited degree of linear dependence. No
correlation was found to 30-day mortality, postoperative pacemaker-implantation and
stroke-rate (r=0.040, p=0.671; r=0.117, p=0.232 and r=-0.025, p=0.792). Overall 30-
day mortality was 14.2%.
Conclusion: The AVCS identifies patients at risk for a relevant paravalvular leak.
AVCS prior to TA-AVI might serve as an additional tool to reconsider the TAVI
indication and valve size to reduce the risk of paravalvular leaks.
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Transcatheter Aortic Valve Replacement: Outcome of Patients with Moderate
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Background: The influence of moderate or severe MR on TAVR outcomes is
unknown.
Methods: This study included 535 consecutive patients undergoing TAVR with a
balloon expandable valve at 2 centers. Patients with moderate or severe MR before
TAVR were compared to patients with none or mild MR. .
Results: A total of 149 patients (28%) presented with concomitant moderate or severe
MR and 386 (72%) had none, trivial or mild MR. Patients with moderate or severe
MR were older (median age 84 vs. 82 years, p = 0.01) and exhibited a higher risk
profile (median STS score 8.2 vs. 7.4 %, p = 0.01). MR improved from moderate or
severe to none or mild at discharge in 79/148 (53%) patients and worsened from none
or mild to moderate or severe in 16/379 (4%). Survival rates for patients with and
without moderate or severe MR at baseline were 85.0% and 93.4% at 30 days, 72.3%
and 79.2% at 1 year, and 53.4% and 51.8% at 3 years, respectively (logrank p = 0.038,
Figure). Moderate or severe MR was an independent risk factor for mortality during
the first 30 days (unadjusted HR 2.32 (95% CI 1.31, 4.11), p < 0.01, adjusted HR 2.25
(1.25, 4.05), p < 0.01), but not after 30 days (unadjusted HR 1.03 (0.57, 1.85), p =
0.92, adjusted HR 1.04 (0.57, 1.90), p = 0.90). At 1 year follow-up, only 4% of the
patients with moderate or severe MR at baseline and 5% of the patients with none or
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